← Leaderboards
R Mark Van Allen
Cornovus Pharmaceuticals, Inc.
$1,018,717
Attributed
$1,018,717
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,018,717 · 1
By mechanism
R44$1,018,717 · 1
Top collaborators
No co-investigators on record.
Most similar at Cornovus Pharmaceuticals, Inc.
Same institution · by research overlap
- Bruce Liang$2,477,183
- Terence Kelly$968,717
Others in their field
Other Emerging Leaders on “Adverse Effects”
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Kristin Aillon · Midwest Research Institute$23,644,534
- Abraham Aizer Brody · New York University School Of Medicine$21,887,280
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$21,828,548
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
Research focus
Adverse EffectsAnimal ModelAreaAwardBaseBlood Pressure ReductionCanis FamiliarisCardiacCardiac MyocytesCardiologyCardioprotectionCaviaCell LineChemical SynthesisChemistryChromatographyClinical LotClinical ResearchClinical TrialsCollaborationsColumn ChromatographyConnecticutConsciousAction Potentials